Tolerability and Safety of 30, 45, and 60 mg of Sublingual Lobeline. - 1

National Institutes of Health (NIH)

Status and phase: Unknown; Phase 1

Conditions: Methamphetamine Dependence

Treatments: Drug: Lobeline

Study type: Interventional

Funder types: NIH

Identifiers

NCT00519259

NIDA-CPU-0009-1

Details and patient eligibility

About

The purpose of this study is to assess safety and pharmacokinetics of sublingual lobeline in healthy normal volunteers.

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Must be able to provide written informed consent
• Must have a body mass index between 18 and 30
• Have no medical contraindications as determined by medical history, physical exam, ECG, hematology and blood chemistry profile, and urinalysis
• Must have a negative drug test at screening and admission
• If female of child bearing potential, must agree to use birth control

Exclusion criteria

• Please contact the site for more information

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind